Continuous renal replacement therapy for congestive heart failure: The wearable continuous ultrafiltration system

ASAIO Journal

Volumn 52, Issue 1, 2006, Pages 59-61

  Gura, Victor ^a   Beizai, Masoud ^b   Ezon, Carlos ^b   Rambod, Edmond ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b National Quality Care Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; CARDIOLOGY; DRUG THERAPY; HOSPITALS; PATIENT TREATMENT; ULTRAFILTRATION;

INTENSIVE CARE UNIT; MORBIDITY; RENAL REPLACEMENT THERAPY; URETERAL LIGATION;

BIOMEDICAL ENGINEERING;

HEPARIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW; BLOOD PUMP; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEVICE; DRUG USE; DYSPNEA; ECONOMIC ASPECT; EXPERIMENTAL THERAPY; FIBER; FILTER; HOSPITAL ADMISSION; INTENSIVE CARE UNIT; LEG SWELLING; LENGTH OF STAY; MORBIDITY; NONHUMAN; QUALITY OF LIFE; RENAL REPLACEMENT THERAPY; SWINE; ULTRAFILTRATION; URETER LIGATION; ANIMAL; BIOENGINEERING; BLOOD FLOW VELOCITY; ELECTROLYTE BALANCE; HEMOFILTRATION; HUMAN; INSTRUMENTATION; METABOLISM; METHODOLOGY; TIME; TREATMENT OUTCOME;

ANIMALS; BLOOD FLOW VELOCITY; HEART FAILURE, CONGESTIVE; HEMOFILTRATION; HUMAN ENGINEERING; HUMANS; RENAL REPLACEMENT THERAPY; SODIUM CHLORIDE; SWINE; TIME FACTORS; TREATMENT OUTCOME; ULTRAFILTRATION; WATER-ELECTROLYTE BALANCE;

EID: 33645735387     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mat.0000195283.58995.83     Document Type: Article

References (20)

1. Lewis CE, Jacobs DR Jr, McCreath H, et al: Weight gain continues in the 1990s: 10-year trends in weight and overweight from the CARDIA Study. Coronary Artery Risk Development in Young Adults. Am J Epidemiol 151: 1172-1181, 2000.
2. American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. Dallas, TX: American Heart Association, 2005.
3. Krumholz HM, Parent EM, Tu N, et al: Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 157: 99-104, 1997.
4. Stevenson LW: Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart Fail 1: 251-257, 1999.
5. Nohria A, Lewis E, Stevenson LW: Medical management of advanced heart failure. JAMA 287: 628-640, 2002.
6. Fonarow GC: Pharmacologic therapies for acutely decompensated heart failure. Rev Cardiovasc Med 3 Suppl 4: S18-27, 2002.
7. Schrier RW, Abraham WT: Hormones and hemodynamics in heart failure. N Engl J Med 341: 577-585, 1999.
8. Levine B, Kalman J, Mayer L, et al: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323: 236-241, 1990.
9. Blake P, Hasegawa Y, Khosla MC, et al: Isolation of "myocardial depressant factor(s)" from the ultrafiltrate of heart failure patients with acute renal failure. ASAIO J 42: M911-915, 1996.
10. Blake P, Paganini EP: Refractory congestive heart failure: Overview and application of extracorporeal ultrafiltration. Adv Ren Replace Ther 3: 166-173, 1996.
11. Coraim FI, Wolner E: Continuous hemofiltration for the failing heart. New Horiz 3: 725-731, 1995.
12. Agostoni PG, Marenzi GC, Pepi M, et al: Isolated ultrafiltration in moderate congestive heart failure. J Am Coll Cardiol 21: 424-431, 1993.
13. Kramer P, Wigger W, Rieger J, et al: Arteriovenous haemofiltration: A new and simple method for treatment of over-hydrated patients resistant to diuretics (in German). Klin Wochenschr 55: 1121-1122, 1977.
14. Silverstein ME, Ford CA, Lysaght MJ, et al: Treatment of severe fluid overload by ultrafiltration. N Engl J Med 291: 747-751, 1974.
15. Donato L, Biagini A, Contini C, et al: Treatment of end-stage congestive heart failure by extracorporeal ultrafiltration. Am J Cardiol 59: 379-380, 1987.
16. Sheppard R, Panyon J, Pohwani AL, et al: Intermittent outpatient ultrafiltration for the treatment of severe refractory congestive heart failure. J Card Fail 10: 380-383, 2004.
17. Francis GS, Siegel RM, Goldsmith SR, et al: Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure; activation of the neurohumoral axis. Ann Intern Med 103: 000-6, 1985.
18. Gottlieb SS, Brater DC, Thomas I, et al: BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105: 1348-1353, 2002.
19. Hillege HL, Girbes ARJ, de Kam PJ, et al: Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102: 203-210, 2000.
20. Weinfeld MS, Chertow GM, Stevenson LW: Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J 138: 285-290, 1999.